$CHEV
Charging Robotics Inc.

2022 Q3 Form 10-Q Financial Statement

#000101738622000348 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $213.0K $151.0K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $37.10K $14.15K $11.29K
YoY Change 1207.79% 368.11%
Operating Profit -$37.10K -$14.15K -$11.29K
YoY Change 1207.79% 368.11%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$37.10K -$14.21K -$11.29K
YoY Change 1207.79% 369.9%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share -$10.49 -$7.59 $0.00
COMMON SHARES
Basic Shares Outstanding 256.7M shares 256.7M shares 256.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $73.18K $73.18K $1.233K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $109.0K $73.18K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $109.0K $73.18K
Total Long-Term Assets $0.00 $0.00
Total Assets $109.0K $73.18K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.40K $4.000K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $190.4K $117.5K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $190.4K $117.5K
Total Long-Term Liabilities
Total Liabilities $190.4K $117.5K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$1.620M -$1.583M
YoY Change
Common Stock $25.67K $25.67K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$81.45K -$44.35K -$30.14K
YoY Change
Total Liabilities & Shareholders Equity $109.0K $73.18K
YoY Change

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$37.10K -$14.21K -$11.29K
YoY Change 1207.79% 369.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$18.75K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $19.98K
YoY Change
NET CHANGE
Cash From Operating Activities -$18.75K
Cash From Investing Activities
Cash From Financing Activities $19.98K
Net Change In Cash $1.233K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$18.75K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001459188
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
fdoc Advanced Subscription Agreement Changes
AdvancedSubscriptionAgreementChanges
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56253
dei Entity Registrant Name
EntityRegistrantName
FUEL DOCTOR HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2274999
dei Entity Address Address Line1
EntityAddressAddressLine1
20 Raul Wallenberg Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Tel Aviv
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
69187
dei City Area Code
CityAreaCode
(647)
dei Local Phone Number
LocalPhoneNumber
558-5564
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73176 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
73176 usd
CY2022Q2 us-gaap Assets
Assets
73176 usd
CY2021Q4 us-gaap Assets
Assets
0 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4000 usd
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
256739363 shares
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18857 usd
CY2022Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
3524 usd
CY2022Q2 fdoc Advanced Subscription Agreement
AdvancedSubscriptionAgreement
110000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
117524 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18857 usd
CY2022Q2 us-gaap Liabilities
Liabilities
117524 usd
CY2021Q4 us-gaap Liabilities
Liabilities
18857 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
256739363 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
256739363 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
256739363 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
256739363 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
25674 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
25674 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1512994 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1512994 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1583016 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1557525 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-44348 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-18857 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73176 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
12400 usd
CY2021Q2 us-gaap Professional Fees
ProfessionalFees
1540 usd
us-gaap Professional Fees
ProfessionalFees
22400 usd
us-gaap Professional Fees
ProfessionalFees
3194 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1751 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1483 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3037 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3177 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
14151 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
3023 usd
us-gaap Operating Expenses
OperatingExpenses
25437 usd
us-gaap Operating Expenses
OperatingExpenses
6371 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14151 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3023 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-25437 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6371 usd
CY2022Q2 fdoc Financial Expenses
FinancialExpenses
54 usd
fdoc Financial Expenses
FinancialExpenses
54 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14205 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3023 usd
us-gaap Net Income Loss
NetIncomeLoss
-25491 usd
us-gaap Net Income Loss
NetIncomeLoss
-6371 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
256739383 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36739363 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
256739383 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36739363 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-12568 usd
us-gaap Profit Loss
ProfitLoss
-6371 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-18939 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11248 usd
us-gaap Profit Loss
ProfitLoss
-11166 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-18857 usd
us-gaap Profit Loss
ProfitLoss
-25491 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-44348 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-15916 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-3023 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-18939 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-30143 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-14205 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-44348 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-25491 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6371 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-14857 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2749 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
3524 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-9120 usd
fdoc Advanced Subscription Agreement Changes
AdvancedSubscriptionAgreementChanges
110000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
73176 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
73176 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73176 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_800_eus-gaap--NatureOfOperations_zSOp6fZWu1r1" style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">NOTE 1 – GENERAL</span></b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 48px"><span style="font-size: 11pt">a.</span></td> <td style="text-align: justify"><span style="font-size: 11pt">Fuel Doctor Holdings, Inc. (“Fuel Doctor” or the “Company”) was incorporated in the state of Delaware on March 25, 2008 as Silver Hill Management Services, inc. On August 24, 2011, the Company entered into an Agreement and Plan of Reorganization (the “Plan”) with Fuel Doctor, LLC, a California Limited Liability company. Pursuant to the terms of the Plan, the members of Fuel Doctor, LLC agreed to transfer all of the issued and outstanding limited units in Fuel Doctor, LLC to the Company in exchange for the issuance of an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20080101__20080325_pdd">9,367,500</span> shares of the Company’s stock, thereby causing Fuel Doctor, LLC to become a wholly owned subsidiary of the Company. Immediately following the closing of the Plan, the Company changed its name to Fuel Doctor Holdings, Inc.</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 48px"><span style="font-size: 11pt">b.</span></td> <td style="text-align: justify"><span style="font-size: 11pt">The COVID-19 pandemic, which originated in China in late 2019, has since spread across the globe and affected the economic condition of most, if not all, countries, including the United States, Israel and many countries in Europe. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. While COVID-19 is still spreading and the final implications of the pandemic are difficult to estimate at this stage, it is clear that it has affected the lives of a large portion of the global population. As of June 30, 2022, the pandemic has caused repeated states of emergency to be declared in various countries, ongoing and extended travel restrictions have been imposed for several months, strict quarantines rules have been established and maintained for an extended period of time in a plethora of jurisdictions and various institutions and companies have been closed and rendered bankrupt. The Company is actively monitoring the pandemic and is taking any necessary measures to respond to the situation in cooperation with the various stakeholders. Due to the uncertainty surrounding the COVID-19 pandemic, the Company will continue to assess the situation, including government-imposed restrictions, market by market. It is not possible at this time to estimate the full impact that the COVID-19 pandemic could have on the Company’s business, the continued spread of COVID-19, and any additional measures taken by governments, health officials or by the Company in response to such spread, could have on the Company’s business, results of operations and financial condition. The COVID-19 pandemic and mitigation measures have also negatively impacted global economic conditions, which, in turn, could adversely affect the Company’s business, results of operations and financial condition. The extent to which the COVID-19 outbreak continues to impact the Company’s financial condition will depend on future developments that are highly uncertain and cannot be predicted, including new government actions or restrictions, new information that may emerge concerning the severity, longevity and impact of the COVID-19 pandemic on economic activity.</span></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2008Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
9367500 shares
us-gaap Basis Of Accounting
BasisOfAccounting
<p id="xdx_842_eus-gaap--BasisOfAccounting_zMRrhuSMUDs" style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; background-color: white"><b>Unaudited Interim Financial Information</b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; background-color: white"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; background-color: white">The Company’s unaudited condensed financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021 and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on April 18, 2022 (the “2021 Annual Report”).</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; background-color: white"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; background-color: white">The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the six months ended June 30, 2022 are not necessarily indicative of the results for the year ending December 31, 2022, or for any future period.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; background-color: white"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; background-color: white">As of June 30, 2022, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2021 Annual Report.</p>
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1557525 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1583016 usd
CY2021Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
300000000 shares
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
256739363 shares
CY2022Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
110000 usd
CY2022Q2 fdoc Private Placement Proposed
PrivatePlacementProposed
270000 usd
CY2022Q2 us-gaap Share Price
SharePrice
0.003
us-gaap Officers Compensation
OfficersCompensation
15000 usd
CY2022Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3524 usd
us-gaap Salaries And Wages
SalariesAndWages
1500 usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
11748 usd
CY2022Q2 us-gaap Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
19980 usd
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.01 pure
CY2022Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
50000 usd

Files In Submission

Name View Source Status
0001017386-22-000348-index-headers.html Edgar Link pending
0001017386-22-000348-index.html Edgar Link pending
0001017386-22-000348.txt Edgar Link pending
0001017386-22-000348-xbrl.zip Edgar Link pending
exhibit_31-1.htm Edgar Link pending
exhibit_31-2.htm Edgar Link pending
exhibit_32-1.htm Edgar Link pending
exhibit_32-2.htm Edgar Link pending
fdoc-20220630.xsd Edgar Link pending
fdoc_2022jun30-10q.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fdoc-20220630_cal.xml Edgar Link unprocessable
fdoc-20220630_def.xml Edgar Link unprocessable
fdoc-20220630_lab.xml Edgar Link unprocessable
fdoc_2022jun30-10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
fdoc-20220630_pre.xml Edgar Link unprocessable